MiNK Therapeutics · conference-presentation
Mink Therapeutics | Investor Day Presentation Deck | 92 slides
92 pages · 4 arc beats · 2 loops
Mink Therapeutics | Investor Day Presentation Deck | 92 slides
MiNK Therapeutics · 2022-11 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
15101520253035404550556065707580859092
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 27 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Statement 4 slides 100% 4/4 slides 100% 4/4 slides · 12 hits — 0/4 slides
75% 3/4 slides 25% 1/4 slides 100% 4/4 slides — 0/4 slides
Proposed Solution 5 slides 100% 5/5 slides 100% 5/5 slides · 25 hits — 0/5 slides
20% 1/5 slides 40% 2/5 slides 100% 5/5 slides 100% 5/5 slides Evidence 13 slides 100% 13/13 slides 100% 13/13 slides · 63 hits — 0/13 slides
53.8% 7/13 slides 23.1% 3/13 slides 100% 13/13 slides 100% 13/13 slides Key Takeaways 5 slides 100% 5/5 slides 100% 5/5 slides · 32 hits — 0/5 slides
20% 1/5 slides — 0/5 slides
100% 5/5 slides — 0/5 slides
Slide inventory
92 every slide · same image gating as the playbook
04
The slide uses a stylized wireframe human body to illustrate the systemic presence of iNKT cells.establish_context
05
The slide uses a simple linear process flow to explain the manufacturing and administration of off-the-shelf cell therapies.present_solution
10
Uses a temple pillar metaphor to represent the evolution of cancer treatment options.present_framework
Open slide detailBeat · Problem Statement
12
The diagram contrasts the state of T cell inhibition (left) with T cell activation (right) via therapeutic antibodies.present_framework
14
Source: Renouf at al, Nat Com 2022. Includes Kaplan-Meier curves (A, B), Forest plot (C), and stacked bar chart of response rates (D).analyze_data
17
The slide uses a process diagram to illustrate the CAR T cell lifecycle and the microenvironment, followed by a table mapping obstacles to solutions.diagnose_problem
Open slide detailLoop · Logic Chain
18
The slide uses a biological process diagram to explain the therapeutic mechanism.present_solution
21
The diagram uses a hub-and-spoke model to show iNKT cells at the center modulating innate (Dendritic, Macrophage, NK) and adaptive (T, B) cells.establish_context
22
The slide uses a biological process diagram to explain the mechanism of action for iNKT cells.present_framework
23
Data presented as Kaplan-Meier survival curves and tumor growth kinetics/bar charts.analyze_data
24
The diagram depicts a biological process flow involving iNKT cells, DCs, MDSCs, and inflammatory monocytes.present_framework
25
The table uses checkmarks, crosses, and question marks to indicate performance/capability across different cell types.compare_peers
27
The slide presents clinical efficacy metrics (ORR, SD, mOS) and safety profile for iNKT cell therapy.analyze_data
28
The data shows a clear trend where the combination of iNKT activator + Fc enhanced CTLA-4 + PD-1 (Group F) results in the lowest number of metastases.analyze_data
29
The slide uses a process flow diagram to show trial progression and a list-based structure for clinical endpoints.present_framework
30
The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the totalanalyze_data
31
The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.analyze_data
32
Includes a table of adverse events, box plots for cytokines (IL-1b, IL-6, CRP), and a longitudinal line chart for IFNy.analyze_data
33
The slide uses a staircase diagram to represent dose escalation levels.present_framework
34
The slide presents a patient cohort table and a specific case study (Patient 6) showing M-spike protein and plasma cell levels over time.illustrate_case
35
The slide presents clinical trial safety data including a table of adverse events and dot plots for inflammatory markers.analyze_data
39
The slide uses a three-column layout to present distinct biological mechanisms supported by experimental data (line and bar charts).summarize
Open slide detailBeat · Key Takeaways
41
Illustrates the mechanism of action for two distinct therapeutic modalities.present_solution
42
The diagram illustrates the interaction between iNKT cells and tumor cells/immune cells via various receptors (CAR, iTCR, NKG2D, DNAM1).present_framework
43
The slide uses a biological process diagram to explain the mechanism of action of the CARDIS platform.present_solution
44
The slide uses a funnel metaphor to show the screening and selection process.present_solution
45
The slide uses a funnel metaphor to show the progression from synthetic phage libraries to final candidates.present_framework
46
The slide uses a bar chart to show the distribution of clones, with a red circle highlighting the 'binders specific activators' category.frame_problem
47
The diagram shows the interaction between tumor cell receptors and iNKT cell receptors, including the secretion of IL15.present_framework
50
The slide uses a Kaplan-Meier survival plot and longitudinal imaging to demonstrate therapeutic efficacy.illustrate_case
51
The slide uses fluorescence microscopy images and an area chart to demonstrate the efficacy of the therapy.illustrate_case
53
The slide uses a circular flow diagram to suggest a cycle of improvement or replacement of existing therapies.propose_solution
55
The slide illustrates the CARDIS platform workflow and the resulting distribution of binders vs non-binders.analyze_data
56
The slide uses a biological process diagram to explain the therapeutic mechanism of iNKT cells.present_solution
57
The slide highlights the scalability of the manufacturing process by showing the enrichment of iNKT cells.diagnose_problem
58
The slide uses a three-column layout to explain the discovery, mechanism of action, and manufacturing scalability of the MiNK-413 therapy.present_solution
60
The slide uses a contrast-pairs framework to highlight the competitive advantage of the company's technology.compare_peers
61
The slide outlines a three-stage process: Cell expansion, Harvest & Purification, and Formulating & Fill/Finish.present_solution
64
The slide uses a 'Our World in Data' chart to provide context for the mortality rates listed on the left.compare_peers
65
The diagram illustrates the biological mechanism of iNKT cells interacting with other immune cells (DC, MDSC, Inflammatory Monocyte) to control secondary bacterdiagnose_problem
66
The slide uses a combination of medical illustration and real-world clinical photography to explain the procedure.establish_context
68
The slide uses a Kaplan-Meier survival curve, a frequency table for adverse events, and box-and-whisker plots for cytokine levels.analyze_data
69
Data presented by Saint John's Cancer Institute for MiNK Therapeutics.analyze_data
73
The slide uses a dual-panel layout to contrast pro-inflammatory responses in solid tumors with anti-inflammatory responses in ARDS.analyze_data
75
The slide uses a visual contrast between conventional T cells (left) and innate T cells (right, boxed) to highlight the research gap.establish_context
76
The slide uses a numbered list format to categorize distinct barriers: tumor heterogeneity, trafficking, microenvironment, and product quality.diagnose_problem
78
The slide uses a visual metaphor of a competition with a trophy to declare iNKT the winner.compare_peers
79
The slide uses a visual comparison framework to contrast iNKT cell capabilities against traditional ACT limitations.present_solution
82
The slide depicts a mechanism of immune evasion via metabolic competition and immunosuppressive signaling.present_framework
83
The slide uses scRNA-seq data to correlate cell states (Steady State, 4h, 72h post-activation) with specific metabolic gene modules.analyze_data
84
Includes a cartoon illustration of a person cooking, likely representing a researcher or experimental process.analyze_data
86
Flow cytometry plots show higher purity/persistence for Gen 2. Bar charts show statistically significant differences (*) in cell count, tumor volume, and metaboanalyze_data
88
The slide uses UMAP dimensionality reduction to visualize gene expression density across cell populations.analyze_data
89
Scientific visualization of immune cell behavior in adipose tissue.illustrate_case
90
Data from Lynch et al. Nature Immunology 2015 and Lynch et al. Immunity 2012.analyze_data
91
The Swiss Army knife is a visual metaphor for the versatility of the cells.establish_context